Oral Presentation ESA-SRB-ANZOS 2025 in conjunction with ENSA

Characteristics and treatment patterns of people with obesity and high cardiometabolic risk: An Australian chart review study (128683)

Samantha L Hocking 1 2 3 , Rachel S Newson 4 , Harrison Lyddiard 5 , Ella S Green 4
  1. Metabolism and Obesity Service Royal Prince Alfred Hospital, Sydney, NSW, Australia
  2. Central Clinical School, University of Sydney, Sydney, NSW, Australia
  3. Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia
  4. Medical Affairs, Eli Lilly Australia, Sydney, NSW, Australia
  5. IQViA Australia, Sydney, NSW, Australia

Aims:Obesity is a prevalent chronic illness with high morbidity. Despite its prevalence, there are limited real-world insights on how people with obesity (PwO) are treated and managed. This study sought to understand obesity management in Australia.

Methods:A retrospective, multi-centre, web-based chart review was conducted with 27 Australian primary and specialist healthcare professionals (HCPs) involved in management of PwO in public and private clinics. HCPs provided deidentified, patient-level data for up to 5 PwO (Body Mass Index [BMI] ≥30 kg/m2) with high cardiometabolic risk. Eligible patients first presented between 01 January 2022 - 31 December 2022, and attended for treatment on ≥3 occasions. Patient background and obesity treatment delivered as first, second and third line of therapy were collected.

Results:Data from 132 PwO were collected. Average age was 45.4 years (SD=12.2) and 54% were female. Mean BMI was 40.3 kg/m2 (SD=7.7) and 45% of patients had a BMI ≥40 kg/m2. Obesity-related conditions were prevalent, with 60% reporting hypertension, 58% dyslipidaemia, and 39% type 2 diabetes. More than 3 obesity-related conditions were reported for 75% of patients with a BMI ≥40 kg/m2. Non-pharmacological intervention was received by 98% of PwO as first line treatment, 57% as second line and 34% as third line. Pharmacological intervention was received by 43% of PwO as first line treatment, 66% as second line and 55% as third line. Surgical intervention was received by 5% of PwO as first line treatment, 11% as second line and 34% as third line.

Conclusions:Australians with high cardiometabolic risk managed in obesity clinics had a very high BMI and multiple obesity-related conditions. Non-pharmacological intervention was prioritised as first line therapy, despite the high BMI and prevalence of obesity-related conditions in this cohort. There is a need for early, evidence-based, highly effective therapy to address the immense burden of obesity in Australia.